ACE-2-COVID V1.0
Research type
Research Study
Full title
The role of mineralocorticoid receptor-antagonists for treatment of patients with confirmed COVID-19
IRAS ID
295648
Contact name
Christian P Subbe
Contact email
Sponsor organisation
BCUH
Duration of Study in the UK
0 years, 9 months, 1 days
Research summary
This is a study to explore the role of Mineralocorticoids in the pathophysiology of patients admitted to hospital with COVID-19. Results from the study will permit pursuing the second stage of the research to explore the feasibility of treatment with Spironolactone and dexamethasone during COVID-19 as a dual therapy. This study involves in the first instance blood test sampling in order to chart levels of cortisol, aldosterone and von Willibrand factor in patients admitted for care to the hospital with a positive COVID-19 test before and after initiation of treatment with Dexamethasone and in relation to other existing treatments that might affect these pathology tests. Blood tests will be taken for these three compounds at regular intervals during their hospital stay in order to chart the levels through the course of the illness.
REC name
Wales REC 5
REC reference
21/WA/0068
Date of REC Opinion
29 Mar 2021
REC opinion
Favourable Opinion